查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1574267

DNA 疫苗市场：按类型、应用、最终用户、交付方法、技术、治疗领域、给药途径- 2025-2030 年全球预测

DNA Vaccine Market by Type, Application, End-User, Delivery Method, Technology, Therapeutic Area, Route of Administration - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年DNA疫苗市值为2.6393亿美元，预计2024年将达到3.0254亿美元，复合年增长率为13.84%，到2030年将达到6.5423亿美元。

DNA疫苗是免疫技术的重要进步，它直接引入基因工程DNA来引发免疫反应。这些疫苗对于对抗传统疫苗所困扰的疾病至关重要，它们描述了更简化的生产流程和持续更长时间的广泛免疫反应。随着新出现的感染疾病和生物恐怖主义威胁等全球健康挑战的加剧，DNA疫苗在历史上一直发挥​​着特殊作用，变得越来越必要。 DNA 疫苗具有广泛的用途，从人类和动物疫苗到癌症和慢性病的治疗，最终用途从个人医疗到公共卫生工作。

主要市场统计
基准年[2023] 26393万美元
预测年份 [2024] 30254万美元
预测年份 [2030] 6.5423亿美元
复合年增长率（%） 13.84%

推动市场成长的关键因素是基因工程技术的进步、研发投入的增加以及逐步适应新疗法的法规环境。世界人口老化和预防保健意识的增强进一步推动了市场需求。新兴市场存在重要机会，公共卫生需求推动创新疫苗接种策略的快速采用。公司可以透过投资当地的製造和分销基础设施来进入这个市场。

然而，挑战依然存在，例如高昂的初始研发成本、疫苗稳定性问题以及公众对基因技术的担忧。此外，由于司法管辖区的差异而造成的监管障碍也构成了重大风险。同时，技术创新集中在加强电穿孔等疫苗传输系统和提高热稳定性以促进分配。专注于扩大 DNA 疫苗免疫抗原性原性的研究倡议有可能解决现有的限制并扩大其适用性。

DNA疫苗市场正处于起步阶段，正在快速发展，因此有必要明确其策略定位。相关人员应优先考虑与生物技术公司和研究机构的合作，以加速创新和市场进入。解决公众和监管机构接受度的复杂挑战也很重要。最终，重视技术灵活性和策略伙伴关係关係并能够灵活应对这些动态的公司可能会在市场格局中取得成功。

市场动态：揭示快速发展的 DNA 疫苗市场的关键市场洞察

DNA 疫苗市场正因供需的动态交互作用而转变。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 对快速且可扩展的疫苗生产方法的需求不断增长
    • 加强法规结构以支持 DNA 疫苗的核准和商业化
    • 加强疫苗开发的公私合营
    • 新兴市场疫苗接种计划的扩大推动市场成长
  • 市场限制因素
    • 医疗保健专业人员和患者对 DNA 疫苗技术的认识和接受度较低
    • 确保 DNA 疫苗在目标细胞中的稳定性和传递的技术挑战
  • 市场机会
    • 感染疾病的日益普及需要开发靶向 DNA 疫苗
    • 开发个人化 DNA 疫苗，提供针对个别患者需求的客製化解决方案
    • 递送技术的进步提高了 DNA 疫苗的功效和可接受性
  • 市场问题
    • 不同地区配送DNA疫苗低温运输物流的复杂性
    • DNA疫苗产业研发成本高，新进入壁垒

波特五力：驾驭 DNA 疫苗市场的策略工具

波特的五力框架是了解 DNA 疫苗市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点，避免潜在的挑战，确保更强大的市场地位。

PESTLE分析：了解 DNA 疫苗市场的外部影响

外部宏观环境因素在塑造 DNA 疫苗市场的表现动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解DNA疫苗市场的竞争状况

DNA 疫苗市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵 DNA 疫苗市场供应商的绩效评估

FPNV定位矩阵是评估DNA疫苗市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议绘製 DNA 疫苗市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，对 DNA 疫苗市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

它也回答重要问题，帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 对快速且可扩展的疫苗生产方法的需求不断增长
      • 加强法规结构以支持 DNA 疫苗的核准和商业化
      • 加强疫苗开发的公私合营
      • 发展中地区疫苗接种计划的扩大推动市场成长
    • 抑制因素
      • 医疗保健专业人员和患者对 DNA 疫苗技术的认识和接受度较低
      • 确保 DNA 疫苗稳定性和递送至目标细胞的技术挑战
    • 机会
      • 感染疾病的传播正在扩大，需要开发靶向 DNA 疫苗。
      • 开发个人化 DNA 疫苗，提供针对个别患者需求的客製化解决方案
      • 递送技术的进步提高了 DNA 疫苗的功效和可接受性
    • 任务
      • 确保不同地区之间运送 DNA 疫苗的低温运输物流的复杂性
      • DNA疫苗产业研发成本高，新进入壁垒
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章 DNA 疫苗市场：依类型

  • 介绍
  • 质体DNA疫苗
  • 重组蛋白疫苗
  • 病毒载体疫苗

第七章 DNA疫苗市场：依应用分类

  • 介绍
  • 过敏
  • 感染疾病
  • 瘤

第八章 DNA 疫苗市场：依最终用户分类

  • 介绍
  • 学术研究所
  • 合约研究组织
  • 製药公司

第九章 DNA疫苗市场：以交付方式

  • 介绍
  • 基因枪
  • 喷射注射器
  • 无针注射
    • 生物喷射器
    • 电穿孔

第10章 DNA疫苗市场：依技术分类

  • 介绍
  • 电穿孔递送
  • 基因枪递送
  • 透过脂质体递送

第十一章 DNA疫苗市场：依治疗领域

  • 介绍
  • 过敏
  • 自体免疫疾病
  • 癌症
  • 感染疾病

第十二章 DNA 疫苗市场：依给药途径

  • 介绍
  • 皮内
  • 肌肉注射
  • 鼻内
  • 皮下的

第十三章 美洲DNA疫苗市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十四章亚太DNA疫苗市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十五章 欧洲、中东和非洲DNA疫苗市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十六章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议
Product Code: MRR-1A1A064C0154

The DNA Vaccine Market was valued at USD 263.93 million in 2023, expected to reach USD 302.54 million in 2024, and is projected to grow at a CAGR of 13.84%, to USD 654.23 million by 2030.

DNA vaccines represent a significant advancement in immunization technology, involving the direct introduction of genetically engineered DNA to produce an immunological response. These vaccines are crucial in addressing diseases that traditional vaccines may struggle with, offering a more streamlined production process with long-lasting and broad immune responses. Historically niche, their necessity has surged amidst rising global health challenges such as emerging infectious diseases and bioterrorism threats. DNA vaccines exhibit a versatile application scope, from human and veterinary vaccines to cancer and chronic disease treatments, with end-uses extending to personal healthcare and public health initiatives.

KEY MARKET STATISTICS
Base Year [2023] USD 263.93 million
Estimated Year [2024] USD 302.54 million
Forecast Year [2030] USD 654.23 million
CAGR (%) 13.84%

Market growth is primarily influenced by advancements in genetic engineering technologies, increasing R&D investments, and a supportive regulatory environment that's gradually adapting to novel therapeutics. An aging global population and heightened awareness of preventive healthcare further bolster market demand. A pivotal opportunity lies in emerging markets, where public health needs catalyze rapid adoption of innovative vaccination strategies. Companies can capitalize here by investing in localized manufacturing and distribution infrastructures.

Challenges remain, such as high initial R&D costs, issues with vaccine stability, and public apprehension concerning genetic technologies. Regulatory hurdles across different jurisdictions also pose significant risks. Meanwhile, innovation can pivot around enhancing vaccine delivery systems, such as electroporation methods, and improving thermal stability for easier distribution. Research initiatives focusing on expanding the immunogenic profile of DNA vaccines could address existing limitations and broaden applicability.

The DNA vaccine market is both nascent and rapidly evolving, demanding keen strategic positioning. Stakeholders should prioritize collaborations with biotech firms and research institutions to fast-track innovation and market entry. Addressing the complex challenge of public and regulatory acceptance will be critical. Ultimately, companies that navigate these dynamics with agility-emphasizing technological flexibility and strategic partnerships-are likely to thrive in the DNA vaccine market landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving DNA Vaccine Market

The DNA Vaccine Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing need for rapid and scalable vaccine production methodologies
    • Enhanced regulatory frameworks supporting the approval and commercialization of DNA vaccines
    • Increasing collaboration between public and private sectors for vaccine development
    • Expansion of vaccination programs in developing regions boosting market growth
  • Market Restraints
    • Low awareness and acceptance of DNA vaccine technology among healthcare professionals and patients
    • Technical challenges in ensuring the stability and delivery of DNA vaccines in target cells
  • Market Opportunities
    • Rising prevalence of infectious diseases necessitating the development of targeted DNA vaccines
    • Development of personalized DNA vaccines offering tailor-made solutions for individual patient needs
    • Advancements in delivery technologies enhancing the effectiveness and acceptance of DNA vaccines
  • Market Challenges
    • Complexities in ensuring cold chain logistics for the distribution of DNA vaccines across different regions
    • Barriers to market entry for new players due to high research and development costs in the DNA vaccine industry

Porter's Five Forces: A Strategic Tool for Navigating the DNA Vaccine Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the DNA Vaccine Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the DNA Vaccine Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the DNA Vaccine Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the DNA Vaccine Market

A detailed market share analysis in the DNA Vaccine Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the DNA Vaccine Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the DNA Vaccine Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the DNA Vaccine Market

A strategic analysis of the DNA Vaccine Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the DNA Vaccine Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., Astellas Pharma Inc., AstraZeneca plc, Bioject Medical Technologies Inc., Emergent BioSolutions, ExcellGene SA, Genentech, Inc., GeneOne Life Science, Inc., GeoVax Labs, Inc., Immunomic Therapeutics, Inc., Inovio Pharmaceuticals, Inc., Johnson & Johnson, Merck & Co., Inc., Novartis AG, OncoSec Medical Incorporated, Profectus BioSciences, Inc., TechnoVax Inc., Vaccibody AS, Vaxess Technologies Inc., and Vical Incorporated.

Market Segmentation & Coverage

This research report categorizes the DNA Vaccine Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Plasmid DNA Vaccine, Recombinant Protein Vaccine, and Viral Vector Vaccine.
  • Based on Application, market is studied across Allergy, Infectious Diseases, and Oncology.
  • Based on End-User, market is studied across Academic & Research Institutes, Contract Research Organizations, and Pharmaceutical Companies.
  • Based on Delivery Method, market is studied across Gene Gun, Jet Injector, and Needle-Free Injection. The Needle-Free Injection is further studied across Biojector and Electroporation.
  • Based on Technology, market is studied across Electroporation Delivery, Gene Gun Delivery, and Liposome-Mediated Delivery.
  • Based on Therapeutic Area, market is studied across Allergy, Autoimmune Disorders, Cancer, and Infectious Diseases.
  • Based on Route of Administration, market is studied across Intradermal, Intramuscular, Intranasal, and Subcutaneous.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing need for rapid and scalable vaccine production methodologies
      • 5.1.1.2. Enhanced regulatory frameworks supporting the approval and commercialization of DNA vaccines
      • 5.1.1.3. Increasing collaboration between public and private sectors for vaccine development
      • 5.1.1.4. Expansion of vaccination programs in developing regions boosting market growth
    • 5.1.2. Restraints
      • 5.1.2.1. Low awareness and acceptance of DNA vaccine technology among healthcare professionals and patients
      • 5.1.2.2. Technical challenges in ensuring the stability and delivery of DNA vaccines in target cells
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising prevalence of infectious diseases necessitating the development of targeted DNA vaccines
      • 5.1.3.2. Development of personalized DNA vaccines offering tailor-made solutions for individual patient needs
      • 5.1.3.3. Advancements in delivery technologies enhancing the effectiveness and acceptance of DNA vaccines
    • 5.1.4. Challenges
      • 5.1.4.1. Complexities in ensuring cold chain logistics for the distribution of DNA vaccines across different regions
      • 5.1.4.2. Barriers to market entry for new players due to high research and development costs in the DNA vaccine industry
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. DNA Vaccine Market, by Type

  • 6.1. Introduction
  • 6.2. Plasmid DNA Vaccine
  • 6.3. Recombinant Protein Vaccine
  • 6.4. Viral Vector Vaccine

7. DNA Vaccine Market, by Application

  • 7.1. Introduction
  • 7.2. Allergy
  • 7.3. Infectious Diseases
  • 7.4. Oncology

8. DNA Vaccine Market, by End-User

  • 8.1. Introduction
  • 8.2. Academic & Research Institutes
  • 8.3. Contract Research Organizations
  • 8.4. Pharmaceutical Companies

9. DNA Vaccine Market, by Delivery Method

  • 9.1. Introduction
  • 9.2. Gene Gun
  • 9.3. Jet Injector
  • 9.4. Needle-Free Injection
    • 9.4.1. Biojector
    • 9.4.2. Electroporation

10. DNA Vaccine Market, by Technology

  • 10.1. Introduction
  • 10.2. Electroporation Delivery
  • 10.3. Gene Gun Delivery
  • 10.4. Liposome-Mediated Delivery

11. DNA Vaccine Market, by Therapeutic Area

  • 11.1. Introduction
  • 11.2. Allergy
  • 11.3. Autoimmune Disorders
  • 11.4. Cancer
  • 11.5. Infectious Diseases

12. DNA Vaccine Market, by Route of Administration

  • 12.1. Introduction
  • 12.2. Intradermal
  • 12.3. Intramuscular
  • 12.4. Intranasal
  • 12.5. Subcutaneous

13. Americas DNA Vaccine Market

  • 13.1. Introduction
  • 13.2. Argentina
  • 13.3. Brazil
  • 13.4. Canada
  • 13.5. Mexico
  • 13.6. United States

14. Asia-Pacific DNA Vaccine Market

  • 14.1. Introduction
  • 14.2. Australia
  • 14.3. China
  • 14.4. India
  • 14.5. Indonesia
  • 14.6. Japan
  • 14.7. Malaysia
  • 14.8. Philippines
  • 14.9. Singapore
  • 14.10. South Korea
  • 14.11. Taiwan
  • 14.12. Thailand
  • 14.13. Vietnam

15. Europe, Middle East & Africa DNA Vaccine Market

  • 15.1. Introduction
  • 15.2. Denmark
  • 15.3. Egypt
  • 15.4. Finland
  • 15.5. France
  • 15.6. Germany
  • 15.7. Israel
  • 15.8. Italy
  • 15.9. Netherlands
  • 15.10. Nigeria
  • 15.11. Norway
  • 15.12. Poland
  • 15.13. Qatar
  • 15.14. Russia
  • 15.15. Saudi Arabia
  • 15.16. South Africa
  • 15.17. Spain
  • 15.18. Sweden
  • 15.19. Switzerland
  • 15.20. Turkey
  • 15.21. United Arab Emirates
  • 15.22. United Kingdom

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2023
  • 16.2. FPNV Positioning Matrix, 2023
  • 16.3. Competitive Scenario Analysis
  • 16.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Amgen Inc.
  • 2. Astellas Pharma Inc.
  • 3. AstraZeneca plc
  • 4. Bioject Medical Technologies Inc.
  • 5. Emergent BioSolutions
  • 6. ExcellGene SA
  • 7. Genentech, Inc.
  • 8. GeneOne Life Science, Inc.
  • 9. GeoVax Labs, Inc.
  • 10. Immunomic Therapeutics, Inc.
  • 11. Inovio Pharmaceuticals, Inc.
  • 12. Johnson & Johnson
  • 13. Merck & Co., Inc.
  • 14. Novartis AG
  • 15. OncoSec Medical Incorporated
  • 16. Profectus BioSciences, Inc.
  • 17. TechnoVax Inc.
  • 18. Vaccibody AS
  • 19. Vaxess Technologies Inc.
  • 20. Vical Incorporated

LIST OF FIGURES

  • FIGURE 1. DNA VACCINE MARKET RESEARCH PROCESS
  • FIGURE 2. DNA VACCINE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DNA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DNA VACCINE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DNA VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL DNA VACCINE MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL DNA VACCINE MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DNA VACCINE MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL DNA VACCINE MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL DNA VACCINE MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL DNA VACCINE MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 19. GLOBAL DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. AMERICAS DNA VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. AMERICAS DNA VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. UNITED STATES DNA VACCINE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 23. UNITED STATES DNA VACCINE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 28. DNA VACCINE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 29. DNA VACCINE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DNA VACCINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DNA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DNA VACCINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DNA VACCINE MARKET DYNAMICS
  • TABLE 7. GLOBAL DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DNA VACCINE MARKET SIZE, BY PLASMID DNA VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DNA VACCINE MARKET SIZE, BY RECOMBINANT PROTEIN VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DNA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DNA VACCINE MARKET SIZE, BY ALLERGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DNA VACCINE MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL DNA VACCINE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL DNA VACCINE MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL DNA VACCINE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL DNA VACCINE MARKET SIZE, BY GENE GUN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL DNA VACCINE MARKET SIZE, BY JET INJECTOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL DNA VACCINE MARKET SIZE, BY BIOJECTOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL DNA VACCINE MARKET SIZE, BY ELECTROPORATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL DNA VACCINE MARKET SIZE, BY ELECTROPORATION DELIVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL DNA VACCINE MARKET SIZE, BY GENE GUN DELIVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL DNA VACCINE MARKET SIZE, BY LIPOSOME-MEDIATED DELIVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL DNA VACCINE MARKET SIZE, BY ALLERGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL DNA VACCINE MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL DNA VACCINE MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL DNA VACCINE MARKET SIZE, BY INTRADERMAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL DNA VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL DNA VACCINE MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL DNA VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS DNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. CANADA DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. CANADA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. MEXICO DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. MEXICO DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. MEXICO DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 77. MEXICO DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 78. MEXICO DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. UNITED STATES DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. UNITED STATES DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. UNITED STATES DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. UNITED STATES DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 85. UNITED STATES DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 86. UNITED STATES DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 87. UNITED STATES DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES DNA VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 99. AUSTRALIA DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. AUSTRALIA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. AUSTRALIA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 104. AUSTRALIA DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 106. AUSTRALIA DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. CHINA DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. CHINA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. CHINA DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. CHINA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 111. CHINA DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 112. CHINA DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 113. CHINA DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 114. CHINA DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. INDIA DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. INDIA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. INDIA DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. INDIA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 119. INDIA DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 120. INDIA DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 121. INDIA DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 122. INDIA DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. INDONESIA DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. INDONESIA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. INDONESIA DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. INDONESIA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 127. INDONESIA DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 128. INDONESIA DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 129. INDONESIA DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 130. INDONESIA DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. JAPAN DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. JAPAN DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. JAPAN DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. JAPAN DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 135. JAPAN DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 136. JAPAN DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 137. JAPAN DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 138. JAPAN DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. MALAYSIA DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. MALAYSIA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. MALAYSIA DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. MALAYSIA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 143. MALAYSIA DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 144. MALAYSIA DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 145. MALAYSIA DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 146. MALAYSIA DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. PHILIPPINES DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. PHILIPPINES DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 149. PHILIPPINES DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. PHILIPPINES DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 151. PHILIPPINES DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 152. PHILIPPINES DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 153. PHILIPPINES DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 154. PHILIPPINES DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 155. SINGAPORE DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. SINGAPORE DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 157. SINGAPORE DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. SINGAPORE DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 159. SINGAPORE DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 160. SINGAPORE DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 161. SINGAPORE DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 162. SINGAPORE DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH KOREA DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH KOREA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH KOREA DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH KOREA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH KOREA DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH KOREA DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH KOREA DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH KOREA DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 171. TAIWAN DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. TAIWAN DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 173. TAIWAN DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. TAIWAN DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 175. TAIWAN DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 176. TAIWAN DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 177. TAIWAN DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 178. TAIWAN DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. THAILAND DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. THAILAND DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 181. THAILAND DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 182. THAILAND DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 183. THAILAND DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 184. THAILAND DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 185. THAILAND DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 186. THAILAND DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 187. VIETNAM DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. VIETNAM DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 189. VIETNAM DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 190. VIETNAM DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 191. VIETNAM DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 192. VIETNAM DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 193. VIETNAM DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 194. VIETNAM DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 204. DENMARK DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. DENMARK DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 206. DENMARK DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 207. DENMARK DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 208. DENMARK DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 209. DENMARK DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 210. DENMARK DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 211. DENMARK DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 212. EGYPT DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. EGYPT DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 214. EGYPT DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 215. EGYPT DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 216. EGYPT DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 217. EGYPT DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 218. EGYPT DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 219. EGYPT DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 220. FINLAND DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. FINLAND DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 222. FINLAND DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 223. FINLAND DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 224. FINLAND DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 225. FINLAND DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 226. FINLAND DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 227. FINLAND DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 228. FRANCE DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. FRANCE DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 230. FRANCE DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 231. FRANCE DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 232. FRANCE DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 233. FRANCE DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 234. FRANCE DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 235. FRANCE DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 236. GERMANY DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. GERMANY DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 238. GERMANY DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 239. GERMANY DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 240. GERMANY DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 241. GERMANY DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 242. GERMANY DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 243. GERMANY DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 244. ISRAEL DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 245. ISRAEL DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 246. ISRAEL DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 247. ISRAEL DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 248. ISRAEL DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 249. ISRAEL DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 250. ISRAEL DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 251. ISRAEL DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 252. ITALY DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 253. ITALY DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 254. ITALY DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 255. ITALY DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 256. ITALY DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 257. ITALY DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 258. ITALY DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 259. ITALY DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 260. NETHERLANDS DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 261. NETHERLANDS DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 262. NETHERLANDS DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 263. NETHERLANDS DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 264. NETHERLANDS DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 265. NETHERLANDS DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 266. NETHERLANDS DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 268. NIGERIA DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 269. NIGERIA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 270. NIGERIA DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 271. NIGERIA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 272. NIGERIA DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 273. NIGERIA DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 274. NIGERIA DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 275. NIGERIA DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 276. NORWAY DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 277. NORWAY DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 278. NORWAY DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 279. NORWAY DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 280. NORWAY DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 281. NORWAY DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 282. NORWAY DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 283. NORWAY DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 284. POLAND DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 285. POLAND DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 286. POLAND DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 287. POLAND DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 288. POLAND DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 289. POLAND DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 290. POLAND DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 291. POLAND DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 292. QATAR DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 293. QATAR DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 294. QATAR DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 295. QATAR DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 296. QATAR DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 297. QATAR DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 298. QATAR DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 299. QATAR DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 300. RUSSIA DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 301. RUSSIA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 302. RUSSIA DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 303. RUSSIA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 304. RUSSIA DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 305. RUSSIA DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 306. RUSSIA DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 307. RUSSIA DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 308. SAUDI ARABIA DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 309. SAUDI ARABIA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 310. SAUDI ARABIA DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 311. SAUDI ARABIA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 312. SAUDI ARABIA DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 313. SAUDI ARABIA DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 314. SAUDI ARABIA DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 315. SAUDI ARABIA DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 316. SOUTH AFRICA DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 317. SOUTH AFRICA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 318. SOUTH AFRICA DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 319. SOUTH AFRICA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 320. SOUTH AFRICA DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 321. SOUTH AFRICA DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 322. SOUTH AFRICA DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 323. SOUTH AFRICA DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 324. SPAIN DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 325. SPAIN DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 326. SPAIN DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 327. SPAIN DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 328. SPAIN DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 329. SPAIN DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 330. SPAIN DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 331. SPAIN DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 332. SWEDEN DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 333. SWEDEN DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 334. SWEDEN DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 335. SWEDEN DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 336. SWEDEN DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 337. SWEDEN DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 338. SWEDEN DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 339. SWEDEN DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 340. SWITZERLAND DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 341. SWITZERLAND DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 342. SWITZERLAND DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 343. SWITZERLAND DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 344. SWITZERLAND DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 345. SWITZERLAND DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 346. SWITZERLAND DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 347. SWITZERLAND DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 348. TURKEY DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 349. TURKEY DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 350. TURKEY DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 351. TURKEY DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 352. TURKEY DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 353. TURKEY DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 354. TURKEY DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 355. TURKEY DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 356. UNITED ARAB EMIRATES DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 357. UNITED ARAB EMIRATES DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 358. UNITED ARAB EMIRATES DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 359. UNITED ARAB EMIRATES DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 360. UNITED ARAB EMIRATES DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 361. UNITED ARAB EMIRATES DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 362. UNITED ARAB EMIRATES DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 363. UNITED ARAB EMIRATES DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 364. UNITED KINGDOM DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 365. UNITED KINGDOM DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 366. UNITED KINGDOM DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 367. UNITED KINGDOM DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 368. UNITED KINGDOM DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 369. UNITED KINGDOM DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 370. UNITED KINGDOM DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 371. UNITED KINGDOM DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 372. DNA VACCINE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 373. DNA VACCINE MARKET, FP